Drug Type Monoclonal antibody |
Synonyms 12G2-Vt9 neutralizing mAb, humanized 12G2-variant 9 + [1] |
Target |
Mechanism FABP4 inhibitors(fatty acid binding protein 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | US | 22 Mar 2024 |